Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions
Autore:
Mathew, V; Grill, DE; Scott, CG; Grantham, JA; Ting, HH; Garratt, KN; Holmes, DR;
Indirizzi:
Mayo Clin, Div Cardiovasc Dis & Internal Med, Rochester, MN USA Mayo ClinRochester MN USA diovasc Dis & Internal Med, Rochester, MN USA
Titolo Testata:
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
fascicolo: 4, volume: 34, anno: 1999,
pagine: 1163 - 1169
SICI:
0735-1097(199910)34:4<1163:TIOAUO>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRANSLUMINAL CORONARY ANGIOPLASTY; ARTERY BYPASS GRAFTS; PALMAZ-SCHATZ STENT; DISTAL EMBOLIZATION; BALLOON ANGIOPLASTY; ATHEROSCLEROSIS; SURGERY; IMPLANTATION; REOPERATION; ATHERECTOMY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Mathew, V Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn 200 1st St SW Rochester MN USA 55905 05 USA
Citazione:
V. Mathew et al., "The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions", J AM COL C, 34(4), 1999, pp. 1163-1169

Abstract

OBJECTIVES The purpose of this study was to evaluate the effect of abciximab use on clinical outcome in aortocoronary vein graft interventions. BACKGROUND Although large randomized trials have demonstrated a significant benefit of abciximab use in the setting of percutaneous coronary interventions, there is relatively little data with respect to the use of this agent in percutaneous vein graft interventions. METHODS Three hundred and forty-three patients were identified; 210 undergoing vein graft intervention without abciximab and 133 patients with abciximab. RESULTS There were differences in baseline clinical and angiographic characteristics between the two groups; advanced age, unstable angina, older vein grafts and thrombus containing lesions were relatively common in both groups. Angiographic and procedural success rates were similar with or withoutthe use of abciximab (89% vs. 92%, p = 0.15, and 85% vs. 91%, p = 0.12, respectively). The in-hospital composite end point of death/Q-wave myocardialinfarction (QWMI)/repeat revascularization was similar between the two groups. Utilizing statistical modeling to adjust for baseline differences between the groups, abciximab use did not influence the cumulative long-term composite end point of death/MI/repeat revascularization. CONCLUSIONS This study demonstrates that in this relatively high-risk population undergoing aortocoronary vein graft interventions, the administration of abciximab periprocedurally does not appear to reduce major adverse clinical events. (J Am Coll Cardiol 1999;34:1163-9) (C) 1999 by the American College of Cardiology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 08:43:31